Rectal Cancer

Drugs in the pipeline: new therapies that could change treatment strategies

Published in Surgery Litigation and Law Weekly, May 2nd, 2008

New drug compounds, and old ones put to new use, offer doctors and patients new hope for treating and preventing cancer. Studies presented at the 2008 Annual Meeting of the American Association for Cancer Research, April 12-16, show promise and progress against brain, colorectal, rectal and ovarian cancers and lymphoma.

A Multidisciplinary Phase II Study of AZD2171 (cediranib), an Oral Pan-VEGF Receptor Tyrosine Kinase Inhibitor, in Patients with Recurrent Glioblastoma: Abstract LB-247

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly

Source: Surgery Litigation and Law Weekly (2008-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry